Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.51 USD | -6.13% | -10.11% | -18.85% |
May. 07 | ClearPoint Neuro, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Earnings Flash (CLPT) CLEARPOINT NEURO Reports Q1 Revenue $7.6M, vs. Street Est of $7M | MT |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.85% | 161M | - | ||
+7.87% | 223B | B | ||
+11.83% | 195B | B- | ||
+18.87% | 144B | B- | ||
+30.03% | 111B | A- | ||
+2.32% | 65.19B | A- | ||
+14.15% | 53.02B | B+ | ||
+2.68% | 50.28B | B+ | ||
+6.60% | 44.15B | A | ||
+1.85% | 36.45B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLPT Stock
- Ratings ClearPoint Neuro, Inc.